Navigation Links
Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology

OXFORD, England, September 10 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced positive results from a phase II clinical study of its anti-allergy technology, ToleroMune(R), in the field of cat allergy. The trial showed that ToleroMune treatment can substantially reduce allergic reactions to the allergen that causes most cat allergies, and importantly was well tolerated by all patients.

Circassia conducted the double-blind study in Germany, where patients with a confirmed history of cat allergies received a single dose of ToleroMune therapy or placebo. The 88 study participants were divided into groups, with each receiving a different dose, either via subcutaneous or intradermal injection to compare the two routes of administration. To test the effect of the treatment, patients received a microscopic dose of cat dander (the main allergen responsible for cat allergies) into their skin several weeks later. Patients who received ToleroMune therapy via the most effective administration route had markedly reduced skin reactions to the cat allergen at all of the five dose levels tested compared with placebo. The most effective dose reduced reactions by over 40%, compared with 10% for placebo. Throughout the study the ToleroMune treatment proved well tolerated, with no serious or severe adverse events experienced in any of the groups, despite the steadily increasing doses.

"These results are extremely encouraging, both for Circassia and the huge number of people who suffer from allergies. Current treatment options address the symptoms only or require repeated administrations over many months under specialist supervision because of the potential for serious and even life-threatening side effects, which is a particularly important issue for cat allergy therapies. Therefore, achieving a marked reduction in allergic responses after just a single dose is remarkable, and we aim to build on this by testing short treatments of several doses in future trials," said Steve Harris, Circassia's CEO. "Our goal for ToleroMune is to provide a range of allergy therapies that effectively and quickly treat the underlying disease while also offering excellent safety. Consequently, these positive clinical results will not only contribute to the development of our cat allergy product, but will also provide the foundations for our other allergy programmes that utilize our ToleroMune technology."

In addition to their potential clinical benefits, Circassia's anti-allergy products would have significant market opportunities. Currently, over 150 million people suffer from allergic rhinitis in the US and Europe and the market for current treatments, despite their limitations, is approximately $12 billion per year. The prevalence of cat-dander allergy is high, with 1-in-6 Americans and nearly 10% of Europeans suffering from the condition. Existing treatments have a number of issues, either providing symptomatic relief only or requiring lengthy supervision by specialist physicians. In contrast, Circassia's ToleroMune technology has the potential to rapidly desensitize sufferers using extremely small sections of allergens (termed T-cell epitopes), which minimizes the potential for adverse reactions.

About Circassia

Circassia is a specialty biopharmaceutical company focused on developing medicines designed to control immune system responses. The company has a highly experienced management team with a proven track record in product development and commercialization, and having successfully completed two fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. The company is also developing its ToleroTrans organ anti-rejection technology, which uses a similar approach to down-regulate immune responses in transplant patients.

For more information please visit

SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
2. Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose
3. TriMix Gel Achieves Success Among Men Who Have Failed to Achieve Erections With Viagra, Levitra and Cialis Type Tablets
4. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
5. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
6. CureDMs Diabetes Therapy Achieves Major Development Milestone
7. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
8. Bionomics Achieves US$1 Million Milestone Payment from Genmab
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
11. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 Developmental, commercial, ... role in boosting the profitability of pharmaceutical products, ... commercial, and regulatory/legal strategies all play a ... says GBI Research . --> ... play a key role in boosting the profitability of pharmaceutical products, ...
(Date:11/24/2015)... November 25, 2015 The hope ... repeated failure of IVF cycles. After failure of over ... and had lost all hopes that she would be able to conceive ever. ... child conceived after failure of over 15 IVF cycles. ... before they decided to take one last attempt with Gaudium IVF ...
(Date:11/24/2015)... , Nov. 24, 2015  In the pharmaceutical ... in an effort to quickly uncover new insights, tactics ... --> --> However, organizations ... market research project and ensure that all rules and ... industry standards. Another major barrier to efficiently launching market ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like ... , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. ... OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon ... programs, launches new Wimbledon Athletics Facebook page to educate the public, ... unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die from ...
(Date:11/25/2015)... Chicago, IL (PRWEB) , ... November 25, 2015 , ... ... the assets of Tri Lite’s personal heating products business. Cozy Products explains ... low-wattage personal heaters that fit in well with the Cozy Products business model: to ...
(Date:11/25/2015)... ... 25, 2015 , ... SCOTTSDALE, AZ) - Today, Dr. ... both surgical and non-surgical treatments, announced the expansion of his private practice capabilities ... , Highly trained and nationally recognized for his natural approach, Dr. Todd ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... decades of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled ... 5-6. , For 65 years, Brillianteen has been a treasured tradition ...
Breaking Medicine News(10 mins):